DataVXAdvanced SciencePaper
journal article·2023-05Open access

Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer

Jia‐Bin Wang, Qing‐Zhu Qiu, Qiao‐Ling Zheng, Ya‐Jun Zhao, Yu Xu, Tao Zhang, Shuan‐Hu Wang, Quan Wang, Qin‐Wen Jin, Yin‐Hua Ye, Ping Li, Jian‐Wei Xie, Jian‐Xian Lin, Jun Lu, Qi‐Yue Chen, Long‐Long Cao, Ying‐Hong Yang, Chao‐Hui Zheng, Chang‐Ming Huang

Advanced Science· Volume 10· Issue 15
Publisher pageOpen full text
Source abstract

Abstract

Abstract The effectiveness of neoadjuvant immune checkpoint inhibitor (ICI) therapy is confirmed in clinical trials; however, the patients suitable for receiving this therapy remain unspecified. Previous studies have demonstrated that the tumor microenvironment (TME) dominates immunotherapy; therefore, an effective TME classification strategy is required. In this study, five crucial immunophenotype‐related molecules (WARS, UBE2L6, GZMB, BATF2, and LAG‐3) in the TME are determined in five public gastric cancer (GC) datasets (n = 1426) and an in‐house sequencing dataset (n = 79). Based on this, a GC immunophenotypic score (IPS) is constructed using the least absolute shrinkage and selection operator (LASSO) Cox, and randomSurvivalForest. IPSLow is characterized as immune‐activated, and IPSHigh is immune‐silenced. Data from seven centers (n = 1144) indicate that the IPS is a robust and independent biomarker for GC and superior to the AJCC stage. Furthermore, patients with an IPSLow and a combined positive score of ≥5 are likely to benefit from neoadjuvant anti‐PD‐1 therapy. In summary, the IPS can be a useful quantitative tool for immunophenotyping to improve clinical outcomes and provide a practical reference for implementing neoadjuvant ICI therapy for patients with GC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Gastric Cancer Management and Outcomes · Cancer Cells and Metastasis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Gastric Surgery Department of General Surgery Fujian Medical University Union Hospital Fuzhou 350001 P. R. China

Ministry of Education Key Laboratory of Gastrointestinal Cancer (Fujian Medical University) Fujian Medical University Fuzhou 350122 P. R. China

Department of Medical Microbiology Fujian Key Laboratory of Tumor Microbiology Fujian Medical University Fuzhou 350122 P. R. China

Department of Pathology Fujian Medical University Union Hospital Fuzhou 350001 P. R. China

Department of Gastrointestinal Surgery West District of the First Affiliated Hospital of University of Science and Technology of China Hefei 230031 P. R. China

Department of Gastrointestinal and Hernia Surgery The First Affiliated Hospital of Kunming Medical University Kunming 650032 P. R. China

Department of Gastrosurgery Liaoning Cancer Hospital & Institute Cancer Hospital of China Medical University Shenyang 110042 P. R. China

Department of Gastrointestinal Surgery The First Affiliated Hospital of Bengbu Medical College Bengbu 233004 P. R. China

Department of Gastrointestinal Surgery The First Hospital of Jilin University Changchun 130061 P. R. China

Department of Gastrointestinal Surgery Guangxi Medical University Affiliated Tumor Hospital Nanning 530021 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Fujian Province · Construction Project of Fujian Province Minimally Invasive Medical Center

References (51)

Show source-provided references
1. 10.1016/j.semcancer.2022.05.01510.1016/j.semcancer.2022.05.015 ↗
2. 10.1177/175628482094877310.1177/1756284820948773 ↗
3. 10.1158/1078-0432.CCR-22-012110.1158/1078-0432.CCR-22-0121 ↗
4. 10.1016/S1470-2045(21)00692-610.1016/S1470-2045(21)00692-6 ↗
5. 10.1038/s41586-022-04508-410.1038/s41586-022-04508-4 ↗
6. 10.1016/j.annonc.2021.08.213310.1016/j.annonc.2021.08.2133 ↗
7. 10.6004/jnccn.2022.000810.6004/jnccn.2022.0008 ↗
8. 10.1126/science.aax018210.1126/science.aax0182 ↗
9. 10.1200/JCO.2022.40.4_suppl.24410.1200/JCO.2022.40.4_suppl.244 ↗
10. 10.1056/NEJMoa220144510.1056/NEJMoa2201445 ↗
11. 10.1007/s11864-021-00893-610.1007/s11864-021-00893-6 ↗
12. 10.1038/nature2134910.1038/nature21349 ↗
13. 10.1158/0008-5472.CAN-08-265410.1158/0008-5472.CAN-08-2654 ↗
14. 10.1158/1078-0432.CCR-15-150710.1158/1078-0432.CCR-15-1507 ↗
15. 10.1016/j.immuni.2018.03.02310.1016/j.immuni.2018.03.023 ↗
16. 10.1016/j.it.2022.04.01010.1016/j.it.2022.04.010 ↗
17. 10.1172/JCI9119010.1172/JCI91190 ↗
18. 10.1172/jci.insight.12690810.1172/jci.insight.126908 ↗
19. 10.1016/j.cell.2019.03.00510.1016/j.cell.2019.03.005 ↗
20. 10.7150/thno.2147110.7150/thno.21471 ↗
21. 10.1038/s41575-019-0126-x10.1038/s41575-019-0126-x ↗
22. 10.1097/CJI.000000000000031610.1097/CJI.0000000000000316 ↗
23. 10.1158/0008-5472.CAN-13-134210.1158/0008-5472.CAN-13-1342 ↗
24. 10.1038/nature1395410.1038/nature13954 ↗
25. 10.1172/JCI7363910.1172/JCI73639 ↗
26. 10.1038/s41568-020-0285-710.1038/s41568-020-0285-7 ↗
27. 10.1093/jnci/djx21310.1093/jnci/djx213 ↗
28. 10.1126/science.aar359310.1126/science.aar3593 ↗
29. 10.1016/j.ccell.2016.02.00410.1016/j.ccell.2016.02.004 ↗
30. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
31. 10.1111/imr.1304410.1111/imr.13044 ↗
32. 10.1038/nature1401110.1038/nature14011 ↗
33. 10.1158/0008-5472.CAN-08-228110.1158/0008-5472.CAN-08-2281 ↗
34. 10.1038/nature2134910.1038/nature21349 ↗
35. 10.1126/scitranslmed.300650410.1126/scitranslmed.3006504 ↗
36. 10.1001/jamaoncol.2018.001310.1001/jamaoncol.2018.0013 ↗
37. 10.1126/scitranslmed.abf510710.1126/scitranslmed.abf5107 ↗
38. 10.1007/s10120-020-01151-810.1007/s10120-020-01151-8 ↗
39. 10.1200/JCO.2021.39.15_suppl.358410.1200/JCO.2021.39.15_suppl.3584 ↗
40. 10.1200/JCO.2021.39.15_suppl.951510.1200/JCO.2021.39.15_suppl.9515 ↗
41. 10.1056/NEJMoa210997010.1056/NEJMoa2109970 ↗
42. 10.1007/s40265-022-01723-110.1007/s40265-022-01723-1 ↗
43. 10.1200/JCO.2021.39.15_suppl.950210.1200/JCO.2021.39.15_suppl.9502 ↗
44. 10.1200/JCO.2017.35.15_suppl.952010.1200/JCO.2017.35.15_suppl.9520 ↗
45. 10.3389/fimmu.2021.78324310.3389/fimmu.2021.783243 ↗
46. 10.1016/j.ejca.2008.10.02610.1016/j.ejca.2008.10.026 ↗
47. 10.1097/SLA.0b013e318216f44910.1097/SLA.0b013e318216f449 ↗
48. 10.1002/cncr.1166010.1002/cncr.11660 ↗
49. 10.1038/nmeth.333710.1038/nmeth.3337 ↗
50. 10.1093/bioinformatics/btq17010.1093/bioinformatics/btq170 ↗
51. 10.1093/nar/gkv00710.1093/nar/gkv007 ↗